{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:10:33Z","timestamp":1789708233058,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18ck0106307h0002"],"award-info":[{"award-number":["18ck0106307h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,6,15]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:p><jats:italic>Purpose<\/jats:italic> To examine the efficacy and safety of triple therapy with eribulin, trastuzumab, and pertuzumab in patients with HER2-positive metastatic breast cancer (MBC) who never received any prior therapy in the first-line metastatic\/advanced setting. <jats:italic>Methods<\/jats:italic> Eribulin 1.4\u00a0mg\/m<jats:sup>2<\/jats:sup> (days 1 and 8), trastuzumab 8\u00a0mg\/kg over 90\u00a0min and 6\u00a0mg\/kg over 30\u00a0min, and pertuzumab 840\u00a0mg\/body over 60\u00a0min and 420\u00a0mg\/body over 30\u00a0min were administered intravenously in 21-day\u00a0cycles. <jats:italic>Results<\/jats:italic> 25 women (median age, 57\u00a0years [range, 41\u201375\u00a0years]) received a median of 10\u00a0cycles (range, 0\u201334\u00a0cycles); 24 had performance status (PS) 0, 1 PS 1, 8 stage IV breast cancer, and 17 recurrence. Lung and liver metastases occurred in 9 and 9 patients, respectively. Median time to treatment failure with eribulin was 9.1\u00a0months (95% confidence interval [CI], 4.3\u201313.9\u00a0months), and median progression-free survival was 23.1\u00a0months (95% CI, 14.4\u201331.8\u00a0months). The overall response rate (complete response [CR]\u2009+\u2009partial response [PR]) was 80.0% (95% CI, 59.3\u201393.2%), and the clinical benefit rate (CR\u2009+\u2009PR\u2009+\u2009stable disease \u226524\u00a0weeks) was 84.0% (95% CI, 63.9\u201395.5%). The most common treatment-emergent adverse events (TEAEs) were alopecia (92.0%), fatigue (68.0%), and sensory peripheral neuropathy (60.0%). Grade 3\/4 TEAEs occurred in 11 patients (44.0%). The only grade 4 TEAE was neutrophil count decreased (16.0%). Neither grade 4 peripheral neuropathy nor febrile neutropenia occurred. <jats:italic>Conclusions<\/jats:italic> ETP therapy showed acceptable efficacy and safety and is a potential first-line therapy for patients with HER2-positive MBC.<\/jats:p>","DOI":"10.1007\/s10637-019-00755-x","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T08:01:35Z","timestamp":1552032095000},"page":"538-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2686-8732","authenticated-orcid":false,"given":"Kenichi","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kimizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the SBCCSG-36 investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,8]]},"reference":[{"issue":"4785","key":"755_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235(4785):177\u2013182","journal-title":"Science"},{"issue":"4905","key":"755_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MFD (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707\u2013712","journal-title":"Science"},{"issue":"2","key":"755_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69\u201390. https:\/\/doi.org\/10.3322\/caac.20107","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"755_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10555-015-9551-7","volume":"34","author":"A McGuire","year":"2015","unstructured":"McGuire A, Brown JA, Kerin MJ (2015) Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev 34(1):145\u2013155. https:\/\/doi.org\/10.1007\/s10555-015-9551-7","journal-title":"Cancer Metastasis Rev"},{"key":"755_CR5","doi-asserted-by":"publisher","unstructured":"Larionob (2018) Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients. Front Oncol 8(89). https:\/\/doi.org\/10.3389\/fonc.2018.00089","DOI":"10.3389\/fonc.2018.00089"},{"issue":"11","key":"755_CR6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783\u2013792","journal-title":"N Engl J Med"},{"issue":"19","key":"755_CR7","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Ant\u00f3n A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23(19):4265\u20134274","journal-title":"J Clin Oncol"},{"issue":"2","key":"755_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, CLEOPATRA Study Group (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109\u2013119. https:\/\/doi.org\/10.1056\/NEJMoa1113216","journal-title":"N Engl J Med"},{"issue":"6","key":"755_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","volume":"14","author":"SM Swain","year":"2013","unstructured":"Swain SM, Kim SB, Cort\u00e9s J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461\u2013471. https:\/\/doi.org\/10.1016\/S1470-2045(13)70130-X","journal-title":"Lancet Oncol"},{"issue":"8","key":"755_CR10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cort\u00e9s J, CLEOPATRA Study Group (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724\u2013734. https:\/\/doi.org\/10.1056\/NEJMoa1413513","journal-title":"N Engl J Med"},{"key":"755_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/CMAR.S40601","volume":"6","author":"MY Ho","year":"2014","unstructured":"Ho MY, Mackey JR (2014) Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res 6:253\u2013259. https:\/\/doi.org\/10.2147\/CMAR.S40601","journal-title":"Cancer Manag Res"},{"issue":"12","key":"755_CR12","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/bjc.2014.554","volume":"111","author":"M Koczywas","year":"2014","unstructured":"Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM (2014) Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer 111(12):2268\u20132274. https:\/\/doi.org\/10.1038\/bjc.2014.554","journal-title":"Br J Cancer"},{"key":"755_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/IJWH.S74462","volume":"7","author":"MK Doherty","year":"2015","unstructured":"Doherty MK, Morris PG (2015) Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy. Int J Women's Health 7:47\u201358. https:\/\/doi.org\/10.2147\/IJWH.S74462","journal-title":"Int J Women's Health"},{"issue":"18","key":"755_CR14","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","volume":"27","author":"LT Vahdat","year":"2009","unstructured":"Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O'Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27(18):2954\u20132961. https:\/\/doi.org\/10.1200\/JCO.2008.17.7618","journal-title":"J Clin Oncol"},{"issue":"25","key":"755_CR15","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1200\/JCO.2009.25.8467","volume":"28","author":"J Cortes","year":"2010","unstructured":"Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roch\u00e9 H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28(25):3922\u20133928. https:\/\/doi.org\/10.1200\/JCO.2009.25.8467","journal-title":"J Clin Oncol"},{"issue":"6","key":"755_CR16","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/annonc\/mdr444","volume":"23","author":"K Aogi","year":"2012","unstructured":"Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, Taguchi K, Sasaki Y, Takashima S (2012) A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 23(6):1441\u20131448. https:\/\/doi.org\/10.1093\/annonc\/mdr444","journal-title":"Ann Oncol"},{"issue":"2","key":"755_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10549-014-2923-9","volume":"146","author":"K McIntyre","year":"2014","unstructured":"McIntyre K, O'Shaughnessy J, Schwartzberg L, Gl\u00fcck S, Berrak E, Song JX, Cox D, Vahdat LT (2014) Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat 146(2):321\u2013328. https:\/\/doi.org\/10.1007\/s10549-014-2923-9","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"755_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.clbc.2014.04.004","volume":"14","author":"S Wilks","year":"2014","unstructured":"Wilks S, Puhalla S, O'Shaughnessy J, Schwartzberg L, Berrak E, Song J, Cox D, Vahdat L (2014) Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin Breast Cancer 14(6):405\u2013412. https:\/\/doi.org\/10.1016\/j.clbc.2014.04.004","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"755_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10549-013-2574-2","volume":"140","author":"LT Vahdat","year":"2013","unstructured":"Vahdat LT, Garcia AA, Vogel C, Pellegrino C, Lindquist DL, Iannotti N, Gopalakrishna P, Sparano JA (2013) Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat 140(2):341\u2013351. https:\/\/doi.org\/10.1007\/s10549-013-2574-2","journal-title":"Breast Cancer Res Treat"},{"issue":"9769","key":"755_CR20","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Di\u00e9ras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C, EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician\u2019s Choice Versus E7389) investigators (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914\u2013923. https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6","journal-title":"Lancet"},{"issue":"6","key":"755_CR21","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33(6):594\u2013601. https:\/\/doi.org\/10.1200\/JCO.2013.52.4892","journal-title":"J Clin Oncol"},{"issue":"3","key":"755_CR22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","volume":"148","author":"C Twelves","year":"2014","unstructured":"Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A (2014) Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 148(3):553\u2013561. https:\/\/doi.org\/10.1007\/s10549-014-3144-y","journal-title":"Breast Cancer Res Treat"},{"issue":"625","key":"755_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1186\/s40064-015-1422-8","volume":"4","author":"J Watanabe","year":"2015","unstructured":"Watanabe J (2015) Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review. Springerplus 4(625):625. https:\/\/doi.org\/10.1186\/s40064-015-1422-8","journal-title":"Springerplus"},{"issue":"2","key":"755_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"755_CR25","unstructured":"CTCAE 4.03. National Cancer Institute https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html. Accessed 19 Jan 2018"},{"issue":"10","key":"755_CR26","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","volume":"24","author":"JJ Lee","year":"2006","unstructured":"Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24(10):1633\u20131642","journal-title":"J Clin Oncol"},{"key":"755_CR27","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): breast Cancer. Fort Washington, PA: National Comprehensive Cancer Network; 2014 https:\/\/wwwnccnorg\/store\/login\/loginaspx? ReturnURL = https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 31 May 2018"},{"issue":"Suppl 3","key":"755_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.6-suppl_3-1","volume":"6","author":"J Crown","year":"2001","unstructured":"Crown J (2001) Docetaxel: overview of an active drug for breast cancer. Oncologist 6(Suppl 3):1\u20134","journal-title":"Oncologist"},{"issue":"2","key":"755_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10549-016-3808-x","volume":"157","author":"K Inoue","year":"2016","unstructured":"Inoue K, Saito T, Okubo K, Kimizuka K, Yamada H, Sakurai T, Ishizuna K, Hata S, Kai T, Kurosumi M (2016) Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance. Breast Cancer Res Treat 157(2):295\u2013305. https:\/\/doi.org\/10.1007\/s10549-016-3808-x","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"755_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-009-0498-7","volume":"119","author":"K Inoue","year":"2010","unstructured":"Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Miura S, Eguchi K, Shinkai T, Ando M, Watanabe T, Masuda N, Ohashi Y, Sano M, Noguchi S (2010) Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 trial group. Breast Cancer Res Treat 119(1):127\u2013136. https:\/\/doi.org\/10.1007\/s10549-009-0498-7","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"755_CR31","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1200\/JCO.2014.57.1745","volume":"33","author":"C Dang","year":"2015","unstructured":"Dang C, Iyengar N, Datko F, D'Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C (2015) Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 33(5):442\u2013447. https:\/\/doi.org\/10.1200\/JCO.2014.57.1745","journal-title":"J Clin Oncol"},{"issue":"1","key":"755_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10549-016-3851-7","volume":"158","author":"LM Smyth","year":"2016","unstructured":"Smyth LM, Iyengar NM, Chen MF, Popper SM, Patil S, Wasserheit-Lieblich C, Argolo DF, Singh JC, Chandarlapaty S, Sugarman SM, Comen EA, Drullinsky PR, Traina TA, Troso-Sandoval T, Baselga J, Norton L, Hudis CA, Dang CT (2016) Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Res Treat 158(1):91\u201397. https:\/\/doi.org\/10.1007\/s10549-016-3851-7","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"755_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13058-016-0773-6","volume":"18","author":"EA Perez","year":"2016","unstructured":"Perez EA, L\u00f3pez-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, Restuccia E, Andersson M (2016) Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET cohort 1 final results. Breast Cancer Res 18(1):126","journal-title":"Breast Cancer Res"},{"issue":"26","key":"755_CR34","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1200\/JCO.2016.70.6267","volume":"35","author":"A Urruticoechea","year":"2017","unstructured":"Urruticoechea A, Rizwanullah M, Im SA, Ruiz ACS, L\u00e1ng I, Tomasello G, Douthwaite H, Badovinac Crnjevic T, Heeson S, Eng-Wong J, Mu\u00f1oz M (2017) Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy. J Clin Oncol 35(26):3030\u20133038. https:\/\/doi.org\/10.1200\/JCO.2016.70.6267","journal-title":"J Clin Oncol"},{"issue":"7","key":"755_CR35","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.21873\/anticanres.12697","volume":"38","author":"K Sakaguchi","year":"2018","unstructured":"Sakaguchi K, Nakatsukasa K, Koyama H, Kato M, Sakuyama A, Matsuda T, Tsunoda N, Fujiwara I, Yamaguchi M, Tanaka H, Onishi K, Onishi M, Yoshino Y, Kikuchi T, Taguchi T (2018) Phase II clinical trial of first-line eribulin plus trastuzumab for advanced or recurrent HER2-positive breast cancer. Anticancer Res 38(7):4073\u20134081. https:\/\/doi.org\/10.21873\/anticanres.12697","journal-title":"Anticancer Res"},{"issue":"19","key":"755_CR36","doi-asserted-by":"publisher","first-page":"14909","DOI":"10.18632\/oncotarget.24504","volume":"9","author":"Y Tono","year":"2018","unstructured":"Tono Y, Ishihara M, Miyahara Y, Tamaru S, Oda H, Yamashita Y, Tawara I, Ikeda H, Shiku H, Mizuno T, Katayama N (2018) Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers. Oncotarget 9(19):14909\u201314921. https:\/\/doi.org\/10.18632\/oncotarget.24504","journal-title":"Oncotarget"}],"updated-by":[{"DOI":"10.1007\/s10637-019-00773-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000}}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00755-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00755-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00755-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:32:11Z","timestamp":1678559531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00755-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,8]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6,15]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00755-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10637-019-00773-9","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,8]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors would like to note the replacement of Fig.\u00a02b, for which Fig. 2a was placed erringly, with appropriate Fig. 2b.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Inoue received grant from Novartis, Pfizer, Chugai, Daiichi-Sankyo, Parexel\/Puma Biotechnology, MSD, Bayer, Lilly, and Eisai during the conduct of the study. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. The study protocol was approved by the Medical Ethics Committees of the participating institutions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}